The Use of Apabetalone in Reducing Cardiovascular Outcomes, Based on the Current Evidence and Trials

The use of apabetalone, a novel therapeutic agent targeting epigenetic regulation, has been the source of much interest in its ability to subvert major adverse cardiovascular events. Derived from BETonMACE, clinical trials have explored its potential benefits in improving cardiovascular health. Apabetalone operates through selective inhibition of bromodomain and extra-terminal domain proteins, influencing gene expression and cellular pathways implicated in cardiovascular disease progression to influence lipid metabolism, downplay oxidative burden and reduce inflammation. The BETonMACE trial recruited patients with type 2 diabetes and recent acute coronary syndrome events. The primary endpoint was the composite of cardiovascular death, MI and stroke. This article explores the various clinical research and outcomes related to apabetalone and its use in the context of its proposed mechanism.